Mohn Cancer Research Laboratory

Promising effect of Lynparza as monotherapy in the Petremac trial

In an interview with journalist Marit Aaby Vebenstad (published 28.06.2022 in the Norwegian oncology journal Brystkreft), Per Eystein Lønning from Mohn Cancer Research Laboratory talks about the promising effect of Lynparza as monotherapy in the treatment of triple negative breast cancer in the clinical trial Petremac.

Bilde viser en tekst fra et tidsskrift med bilde av en mann med hvitt hår
Screenshot of Onkologisk Tidsskrift (28.06.2022)
Onkologisk Tidsskrift

Main content

Read the full interview with Professor Lønning in the journal Brystkreft.

For more information about the Petremac trial and other clinical studies that the research group is working on, please visit the section about personalized therapy of cancer on our website.